Occudo Quantitative Strategies LP Makes New $1.40 Million Investment in Pfizer Inc. (NYSE:PFE)

Occudo Quantitative Strategies LP purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 52,566 shares of the biopharmaceutical company's stock, valued at approximately $1,395,000.

A number of other institutional investors have also modified their holdings of the company. OMERS ADMINISTRATION Corp boosted its holdings in shares of Pfizer by 8.3% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 241,680 shares of the biopharmaceutical company's stock valued at $6,412,000 after buying an additional 18,448 shares in the last quarter. Minot DeBlois Advisors LLC bought a new stake in shares of Pfizer in the 4th quarter valued at about $708,000. Mubadala Investment Co PJSC bought a new stake in shares of Pfizer in the 4th quarter valued at about $3,831,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Pfizer by 8.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,090,774 shares of the biopharmaceutical company's stock valued at $28,934,000 after buying an additional 82,594 shares in the last quarter. Finally, Leigh Baldwin & CO. LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $45,383,000. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

Shares of NYSE PFE opened at $23.09 on Tuesday. The firm has a market cap of $131.25 billion, a PE ratio of 16.37, a PEG ratio of 0.64 and a beta of 0.58. The firm has a fifty day moving average of $23.96 and a 200 day moving average of $25.48. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.45%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is presently 124.64%.

Analyst Ratings Changes

Several brokerages recently commented on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.